Technology ID
              TAB-2640
          Real-time PCR Assays for Selective Detection and Differentiation of B. pertussis, B. parapertussis and B. homesii
E-Numbers
          E-193-2013-0
              Lead Inventor
          Tatti, Kathleen
              Lead IC
          CDC
              Co-Inventors
          Sparks, Kansas
          Tondella, Maria-Lucia
              ICs
          CDC
              Applications
          Diagnostics
              Therapeutic Areas
          Infectious Disease
              Development Status
              - Early-stage
 - In vitro data available
 
CDC researchers developed a real-time PCR assay targeting insertion sequence (IS481) and pertussis toxin subunit 1 (ptxS1) of Bordetella pertussis.  This real-time nucleic acid assay offers rapid, sensitive, and quantitative results.  The employed primers have been validated through extensive diagnostic testing of 41 Bordetella and 64 non-Bordetella clinical isolates.  This technology can be used to diagnose and distinguish B. pertussis, B. parapertussis and B. homesii, the three most common Bordetella human upper respiratory pathogens. A standalone assay or multi-faceted kit may be used.
      
  Commercial Applications
              - Diagnostics for Bordetella pathogens
 - Investigation of acute upper respiratory illness and outbreaks
 
Competitive Advantages
              - Validated for the three major pathogens responsible for Bordetella-related upper respiratory infections
 - Rapid, sensitive and quantitative
 - Easily adapted to kit form
 - Useful as an added, internal control for present Bordetella pertussis diagnostics
 
Licensing Contact: